MedTrace Logo

Upadacitinib for Prurigo Nodularis

NCT06773403 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2026-05-20

No results posted yet for this study

Summary

A single center, open-label study of 25 subjects to assess 24 weeks upadacitinib in patients with moderate-to-severe prurigo nodularis.

Conditions

  • Prurigo Nodularis

Interventions

DRUG

Upadacitinib

All subject start on 15mg. At week 8 subjects may increase to 30mg if the investigators deems it necessary.

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • Psoriasis Treatment Center of Central New Jersey

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-09
Primary Completion
2025-06-06
Completion
2025-06-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06773403 on ClinicalTrials.gov